Autori: Braten Line Skute
| Naslov | What is the Current Clinical Impact of the CYP2CTG Haplotype? (Letter; Early Access) |
| Autori | Ingelman-Sundberg Magnus Jukic Marin M  Braten Line Skute Kringen Marianne Kristiansen Molden Espen
|
| Info | CLINICAL PHARMACOLOGY & THERAPEUTICS, (2023), vol. br. , str. - |
| Ispravka | Web of Science Članak Elečas Rang časopisa Citati: |
     |
| Naslov | Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population (Article) |
| Autori | Braten Line Skute Ingelman-Sundberg Magnus Jukic Marin M Molden Espen Kringen Marianne Kristiansen
|
| Info | CTS-CLINICAL AND TRANSLATIONAL SCIENCE, (2022), vol. 15 br. 9, str. 2135-2145 |
| Projekat | South-Eastern Norway Regional Health Authority; European Union`s Horizon 2020 research and innovation program U-PGx [668353]; Swedish Research Council [2021-02732] |
| Ispravka | Web of Science Članak Elečas Rang časopisa Citati: Web of Science Scopus |
|
|
| Naslov | A Novel CYP2C-Haplotype Associated With Ultrarapid Metabolism of Escitalopram (Article) |
| Autori | Braten Line Skute Haslemo Tore Jukic Marin M Ivanov Maxim Ingelman-Sundberg Magnus Molden Espen Kringen Marianne Kristiansen
|
| Info | CLINICAL PHARMACOLOGY & THERAPEUTICS, (2021), vol. 110 br. 3, str. 786-793 |
| Projekat | South-Eastern Norway Regional Health Authority; Diakonhjemmet Hospital found for research, innovation, and professional development; European Commission [668353] |
| Ispravka | Web of Science Članak Elečas Rang časopisa Citati: Web of Science Scopus |
|
|
| Naslov | Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients (Article) |
| Autori | Braten Line Skute Haslemo Tore Jukic Marin M Ingelman-Sundberg Magnus Molden Espen Kringen Marianne Kristiansen
|
| Info | NEUROPSYCHOPHARMACOLOGY, (2020), vol. 45 br. 3, str. 570-576 |
| Projekat | South-Eastern Norway Regional Health Authority |
| Ispravka | Web of Science Članak Elečas Rang časopisa Citati: Web of Science Scopus |
|
|
